Roche's Tecentriq (atezolizumab) Combination Therapy Receives Health Canada's Approval for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Adults
Shots:
- The approval is based on P-III IMpower150 study results assessing Tecentriq + CT (carboplatin and paclitaxel) with/without Avastin (bevacizumab) vs Bevacizumab and CT in 1-202 patients in a ratio (1:1:1) with stage IV recurrent metastatic non-sq NSCLC- no prior treatment with CT
- The P-III IMpower150 study results: OS (19.2 vs 14.7 mos.); no new safety signals are observed
- Tecentriq is a mAb targeting PD-L1 expressing tumor cells when combined with bevacizumab + CT enhances its ability to restore anti-cancer immunity to combat 1L advanced NSCLC
Ref: PRNewswire | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com